Cardiotoxicity of anthracycline in young breast cancer female patients: The possibility of detection of early cardiotoxicity by TDI

Neoplasma

Volumn 53, Issue 6, 2006, Pages 511-517

  Nagy, A Cs ^a   Tolnay, E ^b   Nagykalnai T ^c   Forster, T ^d  

^a Uzsoki Street Hospital of the Budapest Municipality   (Hungary)

^b 2nd Department of Pest County Institute of Pulmonology   (Hungary)

^c Center of Oncoradiology Budapest   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Anthracycline; Cardiotoxicity; Tissue Doppler imaging

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE; ANTIEMETIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CARDIOTOXICITY; CONTROLLED STUDY; DECELERATION; DIASTOLE; DIASTOLIC DYSFUNCTION; DOPPLER FLOWMETRY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE WALL; HUMAN; LUNG BLOOD FLOW; LUNG VEIN; PALLIATIVE THERAPY; PULSE WAVE; TISSUE DOPPLER IMAGING; VEIN BLOOD FLOW;

EID: 33846393643     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. TAN C, TASAKA H, YU KP, MURPHY ML, KARNOFSKY DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease: clinical evaluation with special reference to childhood leukemia. Cancer 1967; 20(3): 333-353.
2. LEFRAK EA, PITHA J, ROSENHEIM S, GOTTLIEB JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32(2): 302-314.
3. WHEELER DM. Another hypothesis concerning the antitumor activity and cardiotoxicity of daunorubicin (NSC-82151) and adriamycin (NSC-123127). Cancer Chemother Rep 1975; 59(2Pt 1): 258-259.
4. KEEFE DL. Anthracyclin-Induced Cardiomyopathy. Seminars in Oncology 2001; 28 Suppl 12: 2-7.
5. BRISTOW MR, THOMPSON PD, MARTIN RP, MASON JW, BILLINGHAM ME et al. Early anthracycline cardiotoxicity. Am J Med 1978; 65(5): 823-832.
6. VILLANI F, BERETTA G, GUINDANI A. Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals. Cancer Chemother Pharmacol 1979; 3(4): 249-251.
7. STEINHERZ LJ, STEINHERZ PG, TAN C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995; 24(6): 352-361.
8. PAI VB, NAHATA MC. Cardiotoxicity of Chemotherapeutic Agents. Drug Safety 2000; 22(4): 263-302.
9. BU'LOCK FA, MOTT MG, OAKHILL A, MARTIN RP. Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child 1996; 75(5): 416-422.
10. BURSTEIN H, WINER E. Primary care for survivors of breast cancer (review). N Engl J Med 2000; 343(15): 1086-1094.
11. NAGY ACS, TOLNAY E, NAGYKALNAI T, FORSTER T. Cardiotoxicity induced by chemotherapy: possibilities of diagnoses. Orvosi Hetilap 2004; 145(43): 2171-2176.
12. ELBL L, VASOVA I, KRAL Z, NAVRATIL M, SMARDOVA L et al. Echocardiographic evaluation of early and chronic cardiotoxicity in adult patients treated for Hodgkin's disease with ABVD regimen. Neoplasma 2006; 53(1): 586-590 (uncorrected proof).
13. HORÁCEK JM, PUDIL R, TICHY M, JEBAVY L, STRASOVAA et al. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 2005; 52(5): 430-434.
14. BLOOM KR, BINI RM, WILLIAMS CM, SONLEY MJ, GRIBBIN MA. Echocardiography in adriamycin cardiotoxicity. Cancer 1978; 41(4): 1265-1269.
15. IARUSSI D, GALDERISI M, RATTI G, TEDESCO MA, INDOLFI P et al. Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clin Cardiol 2001; 24(10): 663-669.
16. KASS DA. Assessment of diastolic dysfunction. Invasive modalities. Cardiol Clin 2000; 18(3): 571-586.
17. APPLETON CP, HATLE LK, POPP RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insight from a combined hemodynamic and Doppler echocardiography study. J Am Coll Cardiol 1988; 12: 426-440.
18. ISAAZ K, THOMPSON A, ETHEVENOT G, CLOEZ JL, BREMBILLA B et al. Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. J Am Soc Cardiol 1989; 64: 66-75.
19. UEMATSU M, MIYATAKE K, TANAKA N, MATSUDA H, SANO A et al. Myocardial velocity gradient as a new indicator of regional left ventricular contraction: detection by a two-dimensional tissue Doppler imaging technique. J Am Coll Cardiol 1995; 26: 217-223.
20. GULATI VK, KATZ WE, FOLLANSBEE WP, GORCSAN J. Mitral annular descent velocity by tissue Doppler echocardiography as an index of global left ventricular function. Am J Cardiol 1996; 77: 979-984.
21. SHIMIZU Y, UEMATSU M, SHIMIZU H, NAKAMURA K, YAMAGISHI M et al. Peak negative myocardial velocity gradient in early diastole as a noninvasive indicator of left ventricular diastolic function: comparison with transmitral flow velocity indices. J Am Coll Cardiol 1998; 32: 1418-1425.
22. DOROSHOW JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43(2): 460-472.
23. JACKSON JA, REEVES JP, MUNTZ KH, KRUK D, PROUGH RA. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol 1984; 117(1): 140-153.
24. DOROSHOW JH, LOCKER GY, MYERS CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980; 65(1): 128-135.
25. TORRE-AMIONE G, KAPADIA S, LEE J, BIES RD, LEBOVITZ R et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92(6): 1487-1493.
26. HEGEWISH S, WEH HJ, HOSSFELD DK. TNF-induced cardiomyopathy. Lancet 1990; 335(8684): 294-295.
27. KRISCHER JP, EPSTEIN S, CUTHBERTSON DD, GOORIN AM, EPSTEIN ML et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997; 15(4): 1544-1552.
28. BU'LOCK FA, MOTT MG, OAKHILL A, MARTIN RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995; 73(4): 340-350.
29. KAPUSTA L, THIJSSEN JM, GROOT-LOONEN J, ANTONIUS T, MULDER J et al. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol 2000; 26(7): 1099-1108.
30. LIPSHULTZ SE, COLAN SD, GELBER RD, PEREZ-ATAYDE AR, SALLAN SE et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Eng J Med 1991; 324(12): 808-815.
31. LIPSHULTZ SE, LIPSITZ SR, MONE SM, GOORIN AM, SALLAN SE et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Eng J Med 1995; 333(20): 1359-1360.
32. MOREB JS, OBLON DJ. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer 1992; 70(11): 2637-2641.
33. STEINBERG JS, COHEN AJ, WASSERMAN AG, COHEN P, ROSS AM. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987; 60(6): 1213-1218.
34. STEINHERZ LJ, STEINHERZ PG, TAN CT, HELLER G, MURPHY ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266(12): 1672-1677.